FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987213472> ?p ?o ?g. }

• W1987213472 endingPage "3128" @default.
• W1987213472 startingPage "3125" @default.
• W1987213472 abstract "Nitric oxide production in the vascular endothelium is promoted by diverse agonists that transiently increase intracellular Ca2+ concentration and activate the endothelial nitric-oxide synthase (eNOS), a Ca2+/calmodulin-dependent enzyme. eNOS is acylated by the fatty acids myristate and palmitate and is targeted thereby to plasmalemmal signal-transducing domains termed caveolae. eNOS enzyme activity is markedly attenuated by its interactions with caveolin, the structural scaffolding protein of caveolae. We have discovered that in living cells, the eNOS-caveolin heteromeric complex undergoes cycles of dissociation and re-association modulated by Ca2+-mobilizing agonists. Calcium ionophore A23187 and the muscarinic cholinergic agonist carbachol both promote the dissociation of eNOS from caveolin in cultured cells, associated with translocation of eNOS from caveolae. As [Ca2+]i returns to basal levels, eNOS re-associates with caveolin, and the inhibited enzyme complex is then restored to caveolae, a process accelerated by palmitoylation of the enzyme. These data establish an eNOS-caveolin regulatory cycle, wherein enzyme activation is modulated by reversible protein-protein interactions controlled by Ca2+/calmodulin and by enzyme palmitoylation. Alterations in this cycle are likely to have an important influence on nitric oxide-dependent signaling in the vascular wall. Nitric oxide production in the vascular endothelium is promoted by diverse agonists that transiently increase intracellular Ca2+ concentration and activate the endothelial nitric-oxide synthase (eNOS), a Ca2+/calmodulin-dependent enzyme. eNOS is acylated by the fatty acids myristate and palmitate and is targeted thereby to plasmalemmal signal-transducing domains termed caveolae. eNOS enzyme activity is markedly attenuated by its interactions with caveolin, the structural scaffolding protein of caveolae. We have discovered that in living cells, the eNOS-caveolin heteromeric complex undergoes cycles of dissociation and re-association modulated by Ca2+-mobilizing agonists. Calcium ionophore A23187 and the muscarinic cholinergic agonist carbachol both promote the dissociation of eNOS from caveolin in cultured cells, associated with translocation of eNOS from caveolae. As [Ca2+]i returns to basal levels, eNOS re-associates with caveolin, and the inhibited enzyme complex is then restored to caveolae, a process accelerated by palmitoylation of the enzyme. These data establish an eNOS-caveolin regulatory cycle, wherein enzyme activation is modulated by reversible protein-protein interactions controlled by Ca2+/calmodulin and by enzyme palmitoylation. Alterations in this cycle are likely to have an important influence on nitric oxide-dependent signaling in the vascular wall. The endothelial isoform of nitric-oxide synthase (eNOS) 1The abbreviations used are: eNOS: endothelial isoform of nitric-oxide synthase; palm−, palmitoylation-deficient eNOS mutant; OG, octyl glucoside; mAchR, muscarinic acetylcholine receptor; IP, immunoprecipitation(s). is robustly expressed in the vascular endothelium and in cardiac myocytes, and the cellular regulation of eNOS may represent an important determinant of cardiovascular homeostasis (reviewed in Ref. 1Sase K. Michel T. Trends Cardiovasc. Med. 1997; 7: 25-34Crossref Scopus (84) Google Scholar). In endothelial cells and in cardiac myocytes, eNOS is targeted to specialized invaginations of the plasmalemma termed caveolae (2Feron O. Belhassen L. Kobzik L. Smith T.W. Kelly R.A. Michel T. J. Biol. Chem. 1996; 271: 22810-22814Abstract Full Text Full Text PDF PubMed Scopus (598) Google Scholar). Plasmalemmal caveolae serve as sites for the sequestration of signaling proteins and are further characterized by the presence of caveolin, an intrinsic membrane protein that forms a structural “scaffold,” organizing both proteins and lipids within this key membrane organelle (3Couet J. Li S. Okamoto T. Scherer P.E. Lisanti M.P. Trends Cardiovasc. Med. 1997; 4: 103-110Crossref Scopus (111) Google Scholar, 4Li S. Couet J. Lisanti M.P. J. Biol. Chem. 1996; 271: 29182-29190Abstract Full Text Full Text PDF PubMed Scopus (674) Google Scholar). Caveolin directly interacts with several structurally distinct signaling proteins in caveolae, including G proteins and cellular oncogenes (4Li S. Couet J. Lisanti M.P. J. Biol. Chem. 1996; 271: 29182-29190Abstract Full Text Full Text PDF PubMed Scopus (674) Google Scholar) as well as eNOS (2Feron O. Belhassen L. Kobzik L. Smith T.W. Kelly R.A. Michel T. J. Biol. Chem. 1996; 271: 22810-22814Abstract Full Text Full Text PDF PubMed Scopus (598) Google Scholar, 5Michel J.B. Feron O. Sacks D. Michel T. J. Biol. Chem. 1997; 272: 15583-15586Abstract Full Text Full Text PDF PubMed Scopus (512) Google Scholar, 6Ju H. Zou R. Venema V.J. Venema R.C. J. Biol. Chem. 1997; 272: 18522-18525Abstract Full Text Full Text PDF PubMed Scopus (526) Google Scholar, 7Michel J.B. Feron O. Sase K. Prabhakar P. Michel T. J. Biol. Chem. 1997; 272: 25907-25912Abstract Full Text Full Text PDF PubMed Scopus (270) Google Scholar, 8Garcia-Cardena G. Martasek P. Masters B.S.M. Skidd P.M. Couet J. Li S. Lisanti M.P. Sessa W.C. J. Biol. Chem. 1997; 272: 25437-25440Abstract Full Text Full Text PDF PubMed Scopus (694) Google Scholar, 9Feron O. Michel J.B. Sase K. Michel T. Biochemistry. 1998; 37: 193-200Crossref PubMed Scopus (116) Google Scholar). The activity of purified eNOS, a Ca2+/calmodulin-dependent enzyme (10Marletta M.A. Cell. 1994; 78: 927-930Abstract Full Text PDF PubMed Scopus (815) Google Scholar, 11Nathan C. Xie Q.-W. Cell. 1994; 78: 915-918Abstract Full Text PDF PubMed Scopus (2753) Google Scholar), is markedly attenuated by its interaction with caveolin (5Michel J.B. Feron O. Sacks D. Michel T. J. Biol. Chem. 1997; 272: 15583-15586Abstract Full Text Full Text PDF PubMed Scopus (512) Google Scholar, 6Ju H. Zou R. Venema V.J. Venema R.C. J. Biol. Chem. 1997; 272: 18522-18525Abstract Full Text Full Text PDF PubMed Scopus (526) Google Scholar, 7Michel J.B. Feron O. Sase K. Prabhakar P. Michel T. J. Biol. Chem. 1997; 272: 25907-25912Abstract Full Text Full Text PDF PubMed Scopus (270) Google Scholar, 8Garcia-Cardena G. Martasek P. Masters B.S.M. Skidd P.M. Couet J. Li S. Lisanti M.P. Sessa W.C. J. Biol. Chem. 1997; 272: 25437-25440Abstract Full Text Full Text PDF PubMed Scopus (694) Google Scholar, 9Feron O. Michel J.B. Sase K. Michel T. Biochemistry. 1998; 37: 193-200Crossref PubMed Scopus (116) Google Scholar). We have also shown that purified Ca2+/calmodulin can overcome the inhibitory interaction between eNOS and caveolin in vitro(5Michel J.B. Feron O. Sacks D. Michel T. J. Biol. Chem. 1997; 272: 15583-15586Abstract Full Text Full Text PDF PubMed Scopus (512) Google Scholar, 7Michel J.B. Feron O. Sase K. Prabhakar P. Michel T. J. Biol. Chem. 1997; 272: 25907-25912Abstract Full Text Full Text PDF PubMed Scopus (270) Google Scholar, 9Feron O. Michel J.B. Sase K. Michel T. Biochemistry. 1998; 37: 193-200Crossref PubMed Scopus (116) Google Scholar), but the relevance of these observations to the dynamic regulation of eNOS in endothelial cells is less well understood. In vascular endothelial cells and in cardiac myocytes, the cycle of eNOS activation and deactivation is intimately coupled to the changes in intracellular Ca2+ that are promoted by stimulation of diverse G protein-coupled receptors (12Moncada S. Palmer R.M.J. Higgs E.A. Pharmacol. Rev. 1991; 43: 109-142PubMed Google Scholar, 13Vanhoutte P.M. Hypertension. 1989; 13: 658-667Crossref PubMed Scopus (610) Google Scholar). In this report, we describe a series of experiments that have explored the relationships between intracellular Ca2+ regulation and the dynamics of eNOS-caveolin interactions in living cells. We also document the role of eNOS palmitoylation in the reversible caveolar targeting of the eNOS-caveolin complex following muscarinic cholinergic stimulation. cDNA constructs encoding wild-type eNOS and the palmitoylation-deficient eNOS mutant (palm−) have previously been described (14Robinson L.J. Michel T. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 11776-11780Crossref PubMed Scopus (131) Google Scholar). A plasmid construct encoding the muscarinic m2 mAchR cDNA was obtained from T. I. Bonner (National Institute of Mental Health, Bethesda, MD) (15Bonner T.I. Buckley N.J. Young A.C. Brann M.R. Science. 1987; 237: 527-532Crossref PubMed Scopus (1220) Google Scholar). Bovine aortic endothelial cell and COS-7 cell culture conditions and cDNA transfection protocols were as described previously (2Feron O. Belhassen L. Kobzik L. Smith T.W. Kelly R.A. Michel T. J. Biol. Chem. 1996; 271: 22810-22814Abstract Full Text Full Text PDF PubMed Scopus (598) Google Scholar, 5Michel J.B. Feron O. Sacks D. Michel T. J. Biol. Chem. 1997; 272: 15583-15586Abstract Full Text Full Text PDF PubMed Scopus (512) Google Scholar, 9Feron O. Michel J.B. Sase K. Michel T. Biochemistry. 1998; 37: 193-200Crossref PubMed Scopus (116) Google Scholar). The recombinant expression of eNOS and of the m2 mAchR was verified by Western blot and specific muscarinic radioligand binding, respectively, as reported (16Feron O. Smith T.W Michel T. Kelly R.A. J. Biol. Chem. 1997; 272: 17744-17748Abstract Full Text Full Text PDF PubMed Scopus (230) Google Scholar). Transfected COS-7 cells or endothelial cells were extensively washed with phosphate-buffered saline, harvested, pelleted by centrifugation, resuspended in OG buffer (60 mmol/liter OG, 50 mm Tris-HCl, pH 7.4, 125 mm NaCl, 2 mm dithiothreitol, 50 μm EGTA, and protease inhibitors (1 mg/ml leupeptin, 1 mg/ml pepstatin, and 1 mmphenylmethylsulfonyl fluoride)) and sonicated as described previously (2Feron O. Belhassen L. Kobzik L. Smith T.W. Kelly R.A. Michel T. J. Biol. Chem. 1996; 271: 22810-22814Abstract Full Text Full Text PDF PubMed Scopus (598) Google Scholar, 5Michel J.B. Feron O. Sacks D. Michel T. J. Biol. Chem. 1997; 272: 15583-15586Abstract Full Text Full Text PDF PubMed Scopus (512) Google Scholar, 9Feron O. Michel J.B. Sase K. Michel T. Biochemistry. 1998; 37: 193-200Crossref PubMed Scopus (116) Google Scholar). When cell fractionation was performed, cells were first lysed by sonication in a detergent-free hypotonic buffer and separated into soluble and particulate fractions by ultracentrifugation (100,000 × g, 1 h) (9Feron O. Michel J.B. Sase K. Michel T. Biochemistry. 1998; 37: 193-200Crossref PubMed Scopus (116) Google Scholar, 14Robinson L.J. Michel T. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 11776-11780Crossref PubMed Scopus (131) Google Scholar). Aliquots of cell homogenates were incubated with a rabbit caveolin-1 polyclonal antibody (lot 5, Transduction Labs) at a final concentration of 4 μg/ml; antibody titration experiments (not shown) documented that this concentration led to quantitative immunoprecipitation (IP) of caveolin from cell lysates. The isoform specificity and lack of cross-reactivity of these antibodies have been previously established (2Feron O. Belhassen L. Kobzik L. Smith T.W. Kelly R.A. Michel T. J. Biol. Chem. 1996; 271: 22810-22814Abstract Full Text Full Text PDF PubMed Scopus (598) Google Scholar, 5Michel J.B. Feron O. Sacks D. Michel T. J. Biol. Chem. 1997; 272: 15583-15586Abstract Full Text Full Text PDF PubMed Scopus (512) Google Scholar, 9Feron O. Michel J.B. Sase K. Michel T. Biochemistry. 1998; 37: 193-200Crossref PubMed Scopus (116) Google Scholar). After 1 h at 4 °C, protein G-Sepharose beads (50 μl of a 50% slurry) were added to the supernatant for a further 1-h incubation at 4 °C. Bound immune complexes were washed three times with OG buffer and then once with 50 mm Tris-HCl, pH 7.4, 150 mm NaCl. In some experiments, the supernatant fraction (remaining following pelleting of the protein G-Sepharose immune complexes) was precipitated by addition of trichloroacetic acid and buffered with a Tris-HCl solution, pH 7.4. The immunoprecipitates and/or the corresponding supernatant precipitates were then eluted by boiling in Laemmli sample buffer. SDS-polyacrylamide gel electrophoresis on 7.5% polyacrylamide gels, immunoblotting with eNOS or caveolin antibodies (Transduction Labs), and chemiluminescent detection protocols were performed as described previously (2Feron O. Belhassen L. Kobzik L. Smith T.W. Kelly R.A. Michel T. J. Biol. Chem. 1996; 271: 22810-22814Abstract Full Text Full Text PDF PubMed Scopus (598) Google Scholar). As shown in Fig. 1, treatment of endothelial cells with the Ca2+ ionophore A23187 leads to the dissociation of caveolin from eNOS. The fraction of eNOS that is liberated from caveolin by Ca2+ ionophore treatment can be recovered in its entirety from the supernatant fraction following the caveolin immunoprecipitation; there is no change in the recovery of caveolin in these or the other drug treatments (Fig. 1, lower panel). Following addition of the Ca2+ chelator EGTA to the ionophore-activated cells, the eNOS-caveolin complex re-forms, as shown by the quantitative immunoprecipitation of eNOS by the caveolin antibody after Ca2+ chelation (Fig. 1, lanes labeled 75). The re-formation of the inhibitory eNOS-caveolin complex may represent a mechanism whereby the enzyme can become de-activated following the return of intracellular Ca2+ to basal levels. Prolonged agonist treatment of endothelial cells leads also to the translocation of eNOS from caveolae to a soluble subcellular compartment (17Michel T. Li G.K. Busconi L. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 6252-6256Crossref PubMed Scopus (305) Google Scholar, 18Dudek R. Wildhirt S. Suzuki H. Winder S. Bing R.J. Pharmacology. 1995; 50: 257-260Crossref PubMed Scopus (5) Google Scholar, 19Fukuda S.-I. Takaichi S. Naritomi H. Hashimoto N. Nagata I. Nozaki K. Kikuchi H. Brain Res. 1995; 696: 30-36Crossref PubMed Scopus (19) Google Scholar), but the role of caveolin in this enzyme translocation is entirely unknown. It seems plausible that this eNOS translocation represents a means for the desensitization of the enzyme upon prolonged agonist stimulation. We therefore examined the subcellular distribution of the eNOS-caveolin complex following treatment of endothelial cells with the Ca2+ ionophore. In resting endothelial cells, nearly all (>95%) of the eNOS is in the particulate subcellular fraction, and the enzyme can be almost quantitatively immunoprecipitated by antibodies directed against caveolin (Fig. 2). Following treatment of endothelial cells with Ca2+ ionophore and the consequent dissociation of the caveolin-eNOS complex, the newly liberated caveolin-free eNOS is now detected in both particulate and soluble subcellular fractions following differential ultracentrifugation. When the Ca2+ chelator EGTA is subsequently added, eNOS located in both the particulate and soluble subcellular fractions re-associates with caveolin, and the soluble complex is then re-targeted to caveolae, as shown in Fig. 2. Taken together, these data suggest a regulatory cycle in which agonist stimulation initially leads to eNOS activation by the Ca2+/calmodulin-dependent disruption of the eNOS-caveolin heteromeric complex, followed later by enzyme translocation and re-formation of the inhibitory caveolin-eNOS heteromer; finally, this inactive complex is re-targeted to caveolae, ready for another round of agonist activation. Although the agonist-evoked modulation of caveolin-eNOS binding affinity may account for changes in the hydrophobicity of eNOS and explain, in part, the reversible translocation of eNOS to and from caveolae, such a mechanism also probably involves cycles of de-palmitoylation/re-palmitoylation of the enzyme. We have indeed previously reported that eNOS is targetedto plasmalemmal caveolae by palmitoylation (20Shaul P.W. Smart E.J. Robinson L.J. German Z. Yuhanna I.S. Ying Y. Anderson R.G.W. Michel T. J. Biol. Chem. 1996; 271: 6518-6522Abstract Full Text Full Text PDF PubMed Scopus (626) Google Scholar) but also that agonists promote enzyme de-palmitoylation leading to eNOS translocation from caveolae (21Robinson L.J. Busconi L. Michel T. J. Biol. Chem. 1995; 270: 995-998Abstract Full Text Full Text PDF PubMed Scopus (211) Google Scholar). Palmitoylation is a reversible post-translational modification characteristic of diverse signaling proteins targeted to caveolae and involves the addition of the 16-carbon fatty acid palmitate to specific cysteine residues within the protein. Palmitate is attached to signaling proteins via a labile thioester bond, and for eNOS as well as some other signaling proteins, agonist activation promotes de-palmitoylation and protein translocation from caveolae (21Robinson L.J. Busconi L. Michel T. J. Biol. Chem. 1995; 270: 995-998Abstract Full Text Full Text PDF PubMed Scopus (211) Google Scholar, 22Milligan G. Parenti M. Magee A.I. Trends Biochem. Sci. 1995; 20: 181-187Abstract Full Text PDF PubMed Scopus (284) Google Scholar, 23Wedegaertner P.B. Wilson P.T. Bourne H.R. J. Biol. Chem. 1995; 270: 503-506Abstract Full Text Full Text PDF PubMed Scopus (394) Google Scholar). eNOS undergoes palmitoylation at two cysteine residues (Cys15 and Cys26); mutagenesis of these residues to alanine reduces the overall affinity of the enzyme for biological membranes and attenuates the selective targeting of eNOS to caveolae (14Robinson L.J. Michel T. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 11776-11780Crossref PubMed Scopus (131) Google Scholar, 20Shaul P.W. Smart E.J. Robinson L.J. German Z. Yuhanna I.S. Ying Y. Anderson R.G.W. Michel T. J. Biol. Chem. 1996; 271: 6518-6522Abstract Full Text Full Text PDF PubMed Scopus (626) Google Scholar). However, the membrane-associated palm−mutant is still able to bind caveolin (9Feron O. Michel J.B. Sase K. Michel T. Biochemistry. 1998; 37: 193-200Crossref PubMed Scopus (116) Google Scholar), suggesting that this post-translational modification does not affect the eNOS-caveolin interaction per se, even if selective targeting of the palm− eNOS mutant to caveolae is impaired. We devised a series of experiments to explore further the relationships between eNOS palmitoylation, caveolin binding, and enzyme recycling following agonist activation and exploited a heterologous expression system in transiently transfected COS cells. To reconstitute the palm− eNOS mutant with a receptor-coupled eNOS pathway in COS cells, we co-transfected cDNA encoding either wild-type or palm− eNOS mutant, along with a cDNA construct encoding the m2 muscarinic cholinergic receptor (mAchR). We chose to study the m2 mAchR because (a) this receptor is well known to function in a physiologically important pathway that regulates eNOS activation in several cell types (12Moncada S. Palmer R.M.J. Higgs E.A. Pharmacol. Rev. 1991; 43: 109-142PubMed Google Scholar, 13Vanhoutte P.M. Hypertension. 1989; 13: 658-667Crossref PubMed Scopus (610) Google Scholar,16Feron O. Smith T.W Michel T. Kelly R.A. J. Biol. Chem. 1997; 272: 17744-17748Abstract Full Text Full Text PDF PubMed Scopus (230) Google Scholar, 24Kelly R.A. Balligand J.-L. Smith T.W. Circ. Res. 1996; 79: 363-380Crossref PubMed Scopus (629) Google Scholar) and (b) this recombinant receptor has been extensively validated as an activator of phospholipase C (25Zhu X. Birnbaumer L. Proc. Natl. Acad. Sci. U. S. A. 1995; 93: 2827-2831Crossref Scopus (90) Google Scholar, 26Katz A. Wu D. Simon M.I. Nature. 1992; 360: 686-689Crossref PubMed Scopus (419) Google Scholar) leading to transient increases in intracellular Ca2+ levels (27Dell'Acqua M.L. Carroll R.C. Peralta E.G. J. Biol. Chem. 1993; 268: 5676-5685Abstract Full Text PDF PubMed Google Scholar, 28Ishizaka N. Noda M. Kimura Y. Hashii M. Fukuda K. Katayama M. Brown D.A. Higashida H. Pfluegers Arch. Eur. J. Physiol. 1995; 429: 426-433Crossref PubMed Scopus (13) Google Scholar). We found that the muscarinic agonist carbachol induces the dissociation of wild-type eNOS from caveolin in COS cells co-transfected with eNOS and m2 mAchR cDNAs; this process is agonist-dependent and is blocked by the cholinergic antagonist atropine (Fig. 3 A). The carbachol-induced dissociation of the eNOS-caveolin complex shows an appropriate agonist dose dependence, with an EC50 of ∼1 μm (Fig. 3, B and C). It must be emphasized that the eNOS released from the heteromeric immune complex with caveolin is recovered in the supernatant of the immunoprecipitations, indicating that the enzyme is released and not degraded following drug treatments (as shown in Figs. Figure 1, Figure 2, Figure 3). Having validated the pharmacological characteristics of this response, we next turned to a series of time course experiments exploring the agonist-regulated association and dissociation of caveolin from wild-type and palm− eNOS using co-immunoprecipitation protocols. For the wild-type enzyme, treatment of co-transfected COS cells with carbachol led to the rapid dissociation of eNOS from caveolin; the wild-type enzyme became fully dissociated from caveolin within 5 min following the addition of carbachol, after which time the proteins were found to re-associate, with the heteromeric complex entirely reformed by 7–10 min (Fig. 4 A). Although this time course parallels that seen with receptor-mediated nitric oxide release from the vascular endothelium studied in situ (29Malinski T Taha Z. Nature. 1992; 358: 676-678Crossref PubMed Scopus (1029) Google Scholar), it is difficult to directly compare the temporal sequence of these events because of the important differences in experimental conditions. For example, the NO-dependent transient hypotensive response seen following the infusion of acetylcholine in vivo is much less rapid than the cellular responses elicited by muscarinic cholinergic activation in vitro, although there is a generally similar temporal pattern (27Dell'Acqua M.L. Carroll R.C. Peralta E.G. J. Biol. Chem. 1993; 268: 5676-5685Abstract Full Text PDF PubMed Google Scholar, 28Ishizaka N. Noda M. Kimura Y. Hashii M. Fukuda K. Katayama M. Brown D.A. Higashida H. Pfluegers Arch. Eur. J. Physiol. 1995; 429: 426-433Crossref PubMed Scopus (13) Google Scholar). We next performed a series of identically configured time course experiments, now studying the palm− eNOS mutant instead of the wild-type enzyme. In contrast to the wild-type enzyme, even prior to agonist addition a significant fraction of the palm−mutant is found unassociated with caveolin, consistent with the mutant's impaired targeting to caveolae in the resting cell. However, after the addition of carbachol, the entire fraction of the palm− mutant that had been complexed to caveolin rapidly dissociates, and within 5 min, no heteromeric caveolin-palm− eNOS complex could be found, just as for the wild-type enzyme, and the entirety of the eNOS could be recovered in the post-immunoprecipitation supernatant (Fig. 4 B). However, at this point, the palm− eNOS mutant shows a dramatic divergence from the wild-type enzyme: the re-association of the caveolin-palm− complex is markedly delayed. In contrast to the wild-type eNOS, in which the entirety of the enzyme is recovered in a heteromeric complex within 7–10 min, the palm− mutant shows only a sluggish re-formation of the heteromer, a process delayed in its onset and barely at completion a full hour after the addition of drug. There is no substantive change in agonist-mediated Ca2+ transients (assessed using fura-2 epifluoresence) between COS cells transfected with the wild-typeversus palm− mutant eNOS (data not shown). We therefore interpret this marked divergence in the kinetics of re-formation of the heteromeric palm− eNOS-caveolin complex to reflect the essential role for re-palmitoylation in facilitating the re-targeting of eNOS to caveolae, thereby facilitating the protein-protein interactions between eNOS and caveolin that permit the heteromeric complex to re-form. In summary, we have shown for the first time in cells that the eNOS-caveolin complex can be rapidly disrupted and subsequently restored following agonist activation, associated with the reversible translocation of the enzyme. We therefore postulate the existence of a dynamic cycle of eNOS-caveolin interactions initiated by agonist-promoted increases in [Ca2+]i that disrupt the caveolin-eNOS complex, leading to enzyme activation. Following more prolonged agonist stimulation, eNOS is de-palmitoylated (21Robinson L.J. Busconi L. Michel T. J. Biol. Chem. 1995; 270: 995-998Abstract Full Text Full Text PDF PubMed Scopus (211) Google Scholar) and is no longer selectively sequestered in caveolae. The translocated enzyme probably partitions both into noncaveolar plasma membrane and into more hydrophilic regions of the cell, the precise identity of which has not been established. Subsequent to the enzyme's translocation into this more “soluble” cell compartment and following the decline in [Ca2+]i to basal levels, caveolin may once again interact with eNOS, leading to enzyme inhibition. The re-association of eNOS with caveolin may occur either at the membrane level or in the cytosol through which caveolin complexes may shuttle between caveolae and an internalized caveolar vesicle/trans-Golgi network (3Couet J. Li S. Okamoto T. Scherer P.E. Lisanti M.P. Trends Cardiovasc. Med. 1997; 4: 103-110Crossref Scopus (111) Google Scholar, 30Kurzchalia T.V. Dupree P. Parton R.G. Kellner R. Virta H. Lehnert M. Simons K. J. Cell Biol. 1992; 118: 1003-1014Crossref PubMed Scopus (464) Google Scholar, 31Conrad P.A. Smart E. Ying Y.-S. Anderson R.G.W. Bloom G. J. Cell Biol. 1995; 131: 1421-1433Crossref PubMed Scopus (218) Google Scholar). The re-association and re-targeting of the heteromeric eNOS-caveolin complex appears to be accelerated (or stabilized) by enzyme palmitoylation, which takes place either within caveolae or en route to this organelle. The re-palmitoylation of eNOS facilitates rapid and efficient stabilization of the inactivated enzyme in the caveolar environment ready for another cycle of stimulation by agonists. This dynamic cycle of eNOS intracellular regulation adds another level of complexity to the post-translational life history of this vital signaling protein and may represent an important control point for the modulation of NO-dependent signaling in the vascular wall." @default.
• W1987213472 created "2016-06-24" @default.
• W1987213472 creator A5012313192 @default.
• W1987213472 creator A5059376263 @default.
• W1987213472 creator A5072384939 @default.
• W1987213472 creator A5084285813 @default.
• W1987213472 date "1998-02-01" @default.
• W1987213472 modified "2023-10-05" @default.
• W1987213472 title "The Endothelial Nitric-oxide Synthase-Caveolin Regulatory Cycle" @default.
• W1987213472 cites W1522965874 @default.
• W1987213472 cites W1565125984 @default.
• W1987213472 cites W1973018387 @default.
• W1987213472 cites W1978745809 @default.
• W1987213472 cites W1984861193 @default.
• W1987213472 cites W1988793690 @default.
• W1987213472 cites W1996895789 @default.
• W1987213472 cites W1999565215 @default.
• W1987213472 cites W2010100459 @default.
• W1987213472 cites W2020471821 @default.
• W1987213472 cites W2023145731 @default.
• W1987213472 cites W2028880044 @default.
• W1987213472 cites W2033496106 @default.
• W1987213472 cites W2035508242 @default.
• W1987213472 cites W2036842366 @default.
• W1987213472 cites W2053854358 @default.
• W1987213472 cites W2061027645 @default.
• W1987213472 cites W2066231048 @default.
• W1987213472 cites W2068800887 @default.
• W1987213472 cites W2071756355 @default.
• W1987213472 cites W2074406830 @default.
• W1987213472 cites W2084379296 @default.
• W1987213472 cites W2095480781 @default.
• W1987213472 cites W2111718849 @default.
• W1987213472 cites W2146736971 @default.
• W1987213472 cites W2153615786 @default.
• W1987213472 cites W2159930565 @default.
• W1987213472 cites W2167042104 @default.
• W1987213472 cites W85001041 @default.
• W1987213472 cites W2081686903 @default.
• W1987213472 doi "https://doi.org/10.1074/jbc.273.6.3125" @default.
• W1987213472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9452418" @default.
• W1987213472 hasPublicationYear "1998" @default.
• W1987213472 type Work @default.
• W1987213472 sameAs 1987213472 @default.
• W1987213472 citedByCount "346" @default.
• W1987213472 countsByYear W19872134722012 @default.
• W1987213472 countsByYear W19872134722013 @default.
• W1987213472 countsByYear W19872134722014 @default.
• W1987213472 countsByYear W19872134722015 @default.
• W1987213472 countsByYear W19872134722016 @default.
• W1987213472 countsByYear W19872134722017 @default.
• W1987213472 countsByYear W19872134722018 @default.
• W1987213472 countsByYear W19872134722019 @default.
• W1987213472 countsByYear W19872134722020 @default.
• W1987213472 countsByYear W19872134722021 @default.
• W1987213472 countsByYear W19872134722022 @default.
• W1987213472 countsByYear W19872134722023 @default.
• W1987213472 crossrefType "journal-article" @default.
• W1987213472 hasAuthorship W1987213472A5012313192 @default.
• W1987213472 hasAuthorship W1987213472A5059376263 @default.
• W1987213472 hasAuthorship W1987213472A5072384939 @default.
• W1987213472 hasAuthorship W1987213472A5084285813 @default.
• W1987213472 hasBestOaLocation W19872134721 @default.
• W1987213472 hasConcept C112243037 @default.
• W1987213472 hasConcept C178790620 @default.
• W1987213472 hasConcept C181199279 @default.
• W1987213472 hasConcept C185592680 @default.
• W1987213472 hasConcept C2777622882 @default.
• W1987213472 hasConcept C2778326061 @default.
• W1987213472 hasConcept C2992676626 @default.
• W1987213472 hasConcept C519581460 @default.
• W1987213472 hasConcept C55493867 @default.
• W1987213472 hasConcept C86803240 @default.
• W1987213472 hasConcept C95444343 @default.
• W1987213472 hasConceptScore W1987213472C112243037 @default.
• W1987213472 hasConceptScore W1987213472C178790620 @default.
• W1987213472 hasConceptScore W1987213472C181199279 @default.
• W1987213472 hasConceptScore W1987213472C185592680 @default.
• W1987213472 hasConceptScore W1987213472C2777622882 @default.
• W1987213472 hasConceptScore W1987213472C2778326061 @default.
• W1987213472 hasConceptScore W1987213472C2992676626 @default.
• W1987213472 hasConceptScore W1987213472C519581460 @default.
• W1987213472 hasConceptScore W1987213472C55493867 @default.
• W1987213472 hasConceptScore W1987213472C86803240 @default.
• W1987213472 hasConceptScore W1987213472C95444343 @default.
• W1987213472 hasIssue "6" @default.
• W1987213472 hasLocation W19872134721 @default.
• W1987213472 hasOpenAccess W1987213472 @default.
• W1987213472 hasPrimaryLocation W19872134721 @default.
• W1987213472 hasRelatedWork W1946896925 @default.
• W1987213472 hasRelatedWork W1971814334 @default.
• W1987213472 hasRelatedWork W1991996044 @default.
• W1987213472 hasRelatedWork W2374639172 @default.
• W1987213472 hasRelatedWork W2388905353 @default.
• W1987213472 hasRelatedWork W2413415794 @default.
• W1987213472 hasRelatedWork W2487374649 @default.
• W1987213472 hasRelatedWork W4231920966 @default.
• W1987213472 hasRelatedWork W645620972 @default.

• next